Replies to post #287527 on Innovation Pharmaceuticals Inc (IPIX)

[seek the light]

Lilahuna and rrr1.....Both Brilacidin and hydroxychloroquine are good drugs. Hydroxychloroquine has been approved for years; so docs can use it off label. And they are doing so with very positive results. All three of the drugs mentioned yesterday during the press briefing have already been approved by the FDA.

Brilacidin has been tested in humans but not approved yet by the FDA for any indication but it is in my opinion superior to hydroxychloroquine but will have to be approved by the Government lab currently testing it before that can happen. But it is safe and anti inflammatory , antibiotic and an immune modulator. And that would seem to be the perfect drug for Covid19; so i think we will see it moved forward by the FDA.

BTW, i think the FDA may very well approve the very first human trial where the patients after being tested, will stay at home and the docs have hydroxychloroquine delivered to the patients doorstep by FedEx. How cool is that??

[CrazyCravings]

Are you alluding that this administration has a few prospective drugs to premier and the rest are being overlooked?

[Roger 2]

There is no reliable evidence of its efficacy. It’s all nonsense from leaders with no understanding of science, in spite of what they self-promote. A cell membrane is not a virion shell.

Plaquenil is not attacking the "shell".
"Chloroquine, a widely-used anti-malarial and autoimmune disease drug, has recently been reported as a potential broad-spectrum antiviral drug.8,9 Chloroquine is known to block virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.10 Our time-of-addition assay demonstrated that chloroquine functioned at both entry, and at post-entry stages of the 2019-nCoV infection in Vero E6 cells (Fig. 1c, d). Besides its antiviral activity, chloroquine has an immune-modulating activity, which may synergistically enhance its antiviral effect in vivo. Chloroquine is widely distributed in the whole body, including lung, after oral administration. The EC90 value of chloroquine against the 2019-nCoV in Vero E6 cells was 6.90?µM, which can be clinically achievable as demonstrated in the plasma of rheumatoid arthritis patients who received 500?mg administration.11 Chloroquine is a cheap and a safe drug that has been used for more than 70 years and, therefore, it is potentially clinically applicable against the 2019-nCoV.

Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro. Since these compounds have been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease."

https://www.nature.com/articles/s41422-020-0282-0